Reasons for ending protocol treatment
. | High-dose IFN . | Low-dose IFN . |
|---|---|---|
| Overall, n (%) | 171 of 201 (85) | 154 of 206 (75) |
| IFN-related adverse reactions | 76 (44) | 45 (29) |
| CML-related (acceleration or blast crisis) | 40 (23) | 48 (31) |
| Stem cell transplantation | 12 (7) | 20 (13) |
| Indication for imatinib | 23 (13) | 16 (10) |
| Intercurrent other diseases | 7 (4) | 6 (4) |
| Refusal, violation, other | 6 (4) | 12 (8) |
| Unknown | 7 (4) | 7 (5) |
| Over the first year, n (%) | 73 | 59 |
| IFN-related adverse reactions | 43 (59) | 20 (34) |
| CML-related | 15 (21) | 21 (36) |
| Stem cell transplantation | 7 (10) | 8 (14) |
| Indication for imatinib | 2 (3) | 2 (3) |
| Intercurrent other diseases | 3 (4) | 3 (5) |
| Refusal, violation, other | 0 (0) | 3 (5) |
| Unknown | 3 (4) | 2 (3) |
. | High-dose IFN . | Low-dose IFN . |
|---|---|---|
| Overall, n (%) | 171 of 201 (85) | 154 of 206 (75) |
| IFN-related adverse reactions | 76 (44) | 45 (29) |
| CML-related (acceleration or blast crisis) | 40 (23) | 48 (31) |
| Stem cell transplantation | 12 (7) | 20 (13) |
| Indication for imatinib | 23 (13) | 16 (10) |
| Intercurrent other diseases | 7 (4) | 6 (4) |
| Refusal, violation, other | 6 (4) | 12 (8) |
| Unknown | 7 (4) | 7 (5) |
| Over the first year, n (%) | 73 | 59 |
| IFN-related adverse reactions | 43 (59) | 20 (34) |
| CML-related | 15 (21) | 21 (36) |
| Stem cell transplantation | 7 (10) | 8 (14) |
| Indication for imatinib | 2 (3) | 2 (3) |
| Intercurrent other diseases | 3 (4) | 3 (5) |
| Refusal, violation, other | 0 (0) | 3 (5) |
| Unknown | 3 (4) | 2 (3) |